Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Patent number: 8124738Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: GrantFiled: September 26, 2006Date of Patent: February 28, 2012Assignee: Medarex, Inc.Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
-
Publication number: 20120045755Abstract: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1 or SEQ ID NO:12, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2 or SEQ ID NO:13, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier. Also disclosed are prognostic and diagnostic assays.Type: ApplicationFiled: March 14, 2011Publication date: February 23, 2012Applicant: Oregon Health & Science UniversityInventors: Gail M. Clinton, Adam Evans, William D. Henner
-
Publication number: 20120039887Abstract: RNA transcripts representing a fusion of a human SLC45A3 nucleic acid and a human ELK4 nucleic acid that are associated with prostate cancer are described. Compositions and methods useful for detection of fusion transcripts of human SLC45A3 and ELK4 genetic sequences associated with cancer and useful for cancer therapy are provided.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Applicant: CORNELL UNIVERSITYInventors: Mark A. Rubin, Dorothee Pflueger, David S. Rickman
-
Publication number: 20120039889Abstract: An in depth analysis of prostate cancer prostatectomy samples which over-express the ERG oncogene led to the discovery of a novel gene translocation in prostate cancer, between the NDRG1 gene (N-myc downstream regulated gene 1) on chromosome 8 and the ERG oncogene on chromosome 21, leading to the expression of a chimeric NDRG1-ERG protein. Methods and compositions useful for diagnosing and treating prostate cancer characterized by NDRG1-ERG fusion are described.Type: ApplicationFiled: March 8, 2010Publication date: February 16, 2012Applicant: CORNELL UNIVERSITYInventors: Mark A. Rubin, Dorothee Pflueger, David S. Rickman
-
Patent number: 8114965Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.Type: GrantFiled: November 7, 2007Date of Patent: February 14, 2012Assignees: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Publication number: 20120027763Abstract: Antibody for targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1, is disclosed. The antibodies, TBL-CLN1, are monoclonal antibodies which can specifically target and bind to the epitope of SEQ ID NO:1 expressed on cancer cells which further leads to killing of cancer cells. TBL-CLN1 is not conjugated to toxin or cytotoxic molecules, and provides selective killing of cancer cells just by binding to cancer cell surface. Also, disclosed herein is SEQ ID NO: 2 which is an engineered epitope which comprises of polypeptide sequence of SEQ ID NO: 1 and a cysteine residue which is added at the carboxyl end of the SEQ ID NO: 1. The epitope of SEQ ID NO: 2 is used to generate monoclonal antibodies described herein.Type: ApplicationFiled: March 4, 2011Publication date: February 2, 2012Applicant: TRANSGENE BIOTEK LTD.Inventors: Koteswara Rao KOLLIPARA, Ramesh Babu BATCHU
-
Patent number: 8105830Abstract: The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules.Type: GrantFiled: November 5, 2002Date of Patent: January 31, 2012Assignee: Altor BioScience CorporationInventors: Jon A. Weidanz, Kimberlyn F. Card, Linda A. Sherman, Norman R. Klinman, Hing C. Wong
-
Patent number: 8101372Abstract: The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.Type: GrantFiled: December 23, 2008Date of Patent: January 24, 2012Assignee: Agensys, Inc.Inventors: Rene S. Hubert, Arthur B. Raitano, Daniel E. H. Afar, Steve Chappell Mitchell, Mary Faris, Aya Jakobovits
-
Patent number: 8097252Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: January 6, 2011Date of Patent: January 17, 2012Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Patent number: 8097703Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.Type: GrantFiled: June 20, 2006Date of Patent: January 17, 2012Assignee: Medarex, Inc.Inventors: Chetana Rao-Naik, David John King, Jie Liu, Haichun Huang, David B. Passmore, Alasdair Fraser Bell, Josephine M. Cardarelli, Chin Pan, To Uyen Thi Do, Sharline Chen, Dawn M. Tanamachi
-
Patent number: 8093361Abstract: The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.Type: GrantFiled: June 7, 2005Date of Patent: January 10, 2012Assignees: Kyowa Hakko Kirin Co., Ltd, Japan as represented by President of National Cancer CenterInventors: Atsushi Ochiai, Norihiko Shiraishi, Yoko Kato, Toshio Ota, Susume Sekine, Kenya Shitara, Akiko Furuya, So Ohta, Emi Hosaka, Yuka Sasaki
-
Patent number: 8088588Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: GrantFiled: December 3, 2008Date of Patent: January 3, 2012Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8088357Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.Type: GrantFiled: December 1, 2003Date of Patent: January 3, 2012Assignee: Nemod Biotherapeutics GmbH & Co. KGInventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
-
Publication number: 20110319599Abstract: A new gene —MN— and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression.Type: ApplicationFiled: October 30, 2007Publication date: December 29, 2011Inventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
-
Patent number: 8084027Abstract: The present invention provides a combination comprising a compound A of formula (I) as set forth in the specification or a pharmaceutically acceptable salt thereof, and an antibody inhibiting a growth factor or its receptor and/or an antimitotic agent or a derivative or prodrug thereof, useful in the treatment of tumors. The chemical name of compound A is 8-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,4,4-trimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid methylamide.Type: GrantFiled: February 2, 2007Date of Patent: December 27, 2011Assignee: Nerviano Medical Sciences S.r.l.Inventors: Ciro Mercurio, Enrico Pesenti, Maria Grazia Porro, Paolo Pevarello
-
Publication number: 20110311538Abstract: The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor tyrosine kinase in an inactive state thereby antagonizing the activity of the receptor tyrosine kinase.Type: ApplicationFiled: June 5, 2008Publication date: December 22, 2011Applicant: YALE UNIVERSITYInventors: Joseph Schlessinger, Irit Lax, Satoru Yuzawa, Yarden Opatowsky, Yan Yang
-
Patent number: 8071815Abstract: The present disclosure provides methods of diagnosing and staging squamous cell carcinomas, for instance head and neck (HNSCC), by detecting chicken ovalbumin upstream promoter-transcription factor-interacting protein 2 (CTIP2) expression. For example, it is demonstrated herein that expression of CTIP2 is increased in SCC relative to a corresponding normal sample. Also included are kits for detecting SCC, as well as methods for identifying CTIP2 inhibitors.Type: GrantFiled: July 17, 2009Date of Patent: December 6, 2011Inventors: Arup Kumar Indra, Gitali Indra, Joseph Abecassis, Mark Leid
-
Publication number: 20110293614Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.Type: ApplicationFiled: November 24, 2009Publication date: December 1, 2011Inventors: Klaus Elenius, Maija Hollmen, Mark Sliwkowski
-
Patent number: 8062892Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.Type: GrantFiled: June 14, 2010Date of Patent: November 22, 2011Assignee: Millennium Pharmaceuticals, Inc.Inventors: Robert Schlegel, Yan Chen, Xumei Zhao, John E. Monahan, Shubhangi Kamatkar, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch
-
Patent number: 8063187Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: GrantFiled: May 30, 2008Date of Patent: November 22, 2011Assignee: Xencor, Inc.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
-
Patent number: 8062887Abstract: The present invention provides a monoclonal antibody recognizing modification after translation of p53 in a manner specific to a modification site, an antibody microarray comprising the antibody immobilized on a substrate, etc. Disclosed is a monoclonal antibody which reacts specifically with a peptide consisting of an amino acid sequence of at least 6 consecutive amino acids containing a predetermined amino acid residue of the amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid residue is phosphorylated or acetylated, or with a peptide having one to several arbitrary amino acids added to the above peptide, but does not react with the above peptide which is not phosphorylated or acetylated.Type: GrantFiled: March 31, 2006Date of Patent: November 22, 2011Assignees: National University Corporation, Hokkaido University, Genenet Co., Ltd.Inventors: Kazuyasu Sakaguchi, Yoshiro Chuman, Yasuo Akebiyama, Miho Matsukizono, Maki Watanabe, Junichi Tsutsumi
-
Publication number: 20110269636Abstract: Aspects of the invention include methods for identifying patients with HER2+ cancers that are at a heightened risk for developing brain metastasis within three years of having been diagnosed with HER2+ cancer. Some embodiments are methods that include the steps of contacting at least a portion of the tumor tissue from patients with probes that interact with the products of a set of thirteen genes that are expressed in these patients at markedly higher levels than in similarly situated patients that are not a heightened risk for developing brain metastasis within this three year window. In some embodiments the tissue samples are assayed from the presence of RNA indicative of the expression of member of a set of 13 genes identified as being differentially expressed in patients with and without a heightened risk for developing brain metastasis.Type: ApplicationFiled: November 29, 2010Publication date: November 3, 2011Applicant: INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATIONInventors: Sunil Badve, Lang Li, George Sledge, Renata Duchnowaska, Jacek Jassem, Patricia Steeg
-
Patent number: 8044180Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: July 3, 2008Date of Patent: October 25, 2011Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Publication number: 20110256142Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein—said first antibody binds EGFR, —said second antibody binds EGFR, —said first and second antibody are non-cross-blocking, and—the dosage regimen is such that CDC is obtained at the tumor site.Type: ApplicationFiled: September 5, 2008Publication date: October 20, 2011Applicant: GENMAB A/SInventors: Jan Van De Winkel, Paul Parren, Willem Karel Bleeker, Klaus Edvardsen, Jeroen Lammerts Van Bueren, Thomas Valerius, Michael Dechant, Wencke Weisner, Sven Berger
-
Patent number: 8039595Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: January 9, 2009Date of Patent: October 18, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Patent number: 8039594Abstract: Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.Type: GrantFiled: March 23, 2006Date of Patent: October 18, 2011Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Beka Solomon, Sara Orgad, Itai Benhar, Ronit Rosenfeld
-
Patent number: 8030455Abstract: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.Type: GrantFiled: December 22, 2009Date of Patent: October 4, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventor: Giulia Kennedy
-
Publication number: 20110239316Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: December 2, 2009Publication date: September 29, 2011Inventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Publication number: 20110236412Abstract: A method for preserving a polypeptide comprises (i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said polypeptide wherein the concentration of polyethyleneimine is 25 ?M or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1 M; and (ii) drying the solution to form an amorphous solid matrix comprising said polypeptide.Type: ApplicationFiled: September 24, 2009Publication date: September 29, 2011Applicant: Stabilitech Ltd.Inventor: Jeffrey Drew
-
Publication number: 20110229479Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: September 3, 2009Publication date: September 22, 2011Applicants: THE JOHNS HOPKINS UNIVERSITY, DUKE UNIVERSITYInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan
-
Publication number: 20110229478Abstract: The present invention relates to compositions and methods for treating neoplasms in mammals, particularly humans. More particularly, the present invention provides for methods for preventing, treating or delaying neoplasm in a mammal using an ErbB-3 protein, a nucleic acid encoding an ErbB-3 protein or a functional fragment thereof. The present invention also provides for an isolated nucleic acids encoding an extracellular domain of the ErbB-3 protein, or a functional fragment thereof, substantially purified extracellular domain of the ErbB-3 protein, or a functional fragment thereof and antibodies that bind to an epitope in an extracellular domain of the ErbB-3 protein, or a functional fragment thereof. The present invention further provides for pharmaceutical compositions and/or vaccines comprising the extracellular domain of the ErbB-3 protein, or a functional fragment thereof, or nucleic acids encoding and antibodies binding to such extracellular domain or functional fragments thereof.Type: ApplicationFiled: February 25, 2011Publication date: September 22, 2011Applicant: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY LIMITEDInventor: MINGDONG ZHOU
-
Publication number: 20110229480Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer, for monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer treatment, and for drug development.Type: ApplicationFiled: September 3, 2009Publication date: September 22, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Patent number: 8017736Abstract: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.Type: GrantFiled: January 26, 2009Date of Patent: September 13, 2011Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8012476Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: January 21, 2010Date of Patent: September 6, 2011Assignees: MedImmune, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 8012697Abstract: The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3, particularly of extracellular annexin A3 with highly specific antibodies, particularly with monoclonal antibodies. The present invention further refers to a test reagent comprising such antibodies.Type: GrantFiled: June 11, 2007Date of Patent: September 6, 2011Assignee: ProteoSys AGInventor: Andre Schrattenholz
-
Patent number: 8012945Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor.Type: GrantFiled: December 10, 2007Date of Patent: September 6, 2011Assignee: Vanderbilt UniversityInventors: Dennis E. Hallahan, Raymond Mernaugh
-
Publication number: 20110213128Abstract: The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ ID NO: 1, particularly a polynucleotide of the nucleotide sequence of SEQ ID NO: 2.Type: ApplicationFiled: January 12, 2011Publication date: September 1, 2011Applicants: NEC CORPORATION, Masahiko KurodaInventors: Akira SAITO, Masahiko Kuroda
-
Patent number: 8003761Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: January 22, 2008Date of Patent: August 23, 2011Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Patent number: 8003098Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.Type: GrantFiled: February 22, 2007Date of Patent: August 23, 2011Assignee: Oncotherapy Science, Inc.Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima, Yoshiro Kishi, Motoki Kuhara, Shiyo Nishida, Midori Shinohara
-
Patent number: 8003763Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.Type: GrantFiled: December 22, 2008Date of Patent: August 23, 2011Assignee: Biogen IDEC MA Inc.Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
-
Publication number: 20110200525Abstract: The presently disclosed subject matter provides ligands for detecting and imaging cancer cells and tumors, and for guided delivery of an active agent to cancer cells and tumors. In some embodiments the ligands comprise an antibody fragment, wherein the antibody fragment comprises a VHH domain. In some embodiments a composition is provided for targeting of cancer cells or tumors. Also provided are methods for delivery of a composition to a target tissue or tumor in a subject. Also provided are methods for imaging a target tissue or tumor in a subject. In some embodiments methods for treating a tumor in a subject are provided. Also provided are methods for diagnosing a tumor in a subject.Type: ApplicationFiled: October 9, 2009Publication date: August 18, 2011Inventors: Edward F. Patz, JR., Elizabeth B. Gottlin, Michael J. Campa
-
Patent number: 7999161Abstract: Provided herein are methods and system to increase selective thermomechanical damage to a biological body, such as a cancer cell or cell associated with a pathophysiological condition. The biological body or cancer cell is specifically targeted with nanoparticulates comprising one or more targeting moieties which form nanoparticulate clusters thereon or therewithin. Pulsed electromagnetic radiation, e.g., optical radiation, having a wavelength spectrum selected for a peak wavelength near to or matching a peak absorption wavelength of the nanoparticulates selectively heats the nanoparticulates thereby generating vapor microbubbles around the clusters causing damage to the targets without affecting any surrounding medium or normal cells or tissues. Also provided is a method of treating leukemia using the methods and system described herein.Type: GrantFiled: January 22, 2006Date of Patent: August 16, 2011Inventors: Alexander Oraevsky, Dmitri Lapotko
-
Patent number: 7989171Abstract: An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A(1-4)-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional analogues capable of binding to an antigenic epitope within the A(1-4)-D region of human tenascin.Type: GrantFiled: February 16, 2005Date of Patent: August 2, 2011Assignee: Tecnogen S.C.P.A.Inventors: Rita De Santis, Angela Pelliccia, Giovanna Palombo, Paolo Carminati
-
Publication number: 20110183336Abstract: Methods of-identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype and compositions for treating identified basal or luminal cancers.Type: ApplicationFiled: April 26, 2010Publication date: July 28, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: JOE W. GRAY, DEBOPRIYA DAS, WEN-LIN KUO, NICHOLAS J. WANG, RICHARD M. NEVE, PAUL T. SPELLMAN, JANE FRIDLYAND, KOEI CHIN, ZHI HU
-
Patent number: 7985843Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.Type: GrantFiled: October 30, 2007Date of Patent: July 26, 2011Assignee: Corixa CorporationInventors: Gary R. Fanger, Steven P. Fling
-
Publication number: 20110176996Abstract: Compositions and methods are provided for the diagnosis, treatment, and medical management of cancers. The methods include the use of antibodies and other binding molecules that specifically bind to one or more nucleotide salvage pathway enzymes (SPEs) selected from the group consisting of adenine phosphoribosyltransferase (APRT), hypoxanthine-guanine phosphoribosyltransferase (HGPRT), deoxycytidine kinase (dCK); and thymidine kinase 1 (TK1) and complexes comprising SPEs, for detection of the SPE(s) on or in cancer cells and/or on or in body fluids and tissues of cancer patients. Binding of SPEs is useful in the methods provided herein for diagnosing cancer, determining prognosis of cancer and assessing the effectiveness of cancer treatments. Immunoassay systems for use in the methods are also provided, including sandwich immunoassays. In addition, an amino acid sequence comprising a novel TK1 binding site is provided, as well as nucleotide sequences encoding it.Type: ApplicationFiled: December 30, 2010Publication date: July 21, 2011Applicant: Brigham Young UniversityInventors: Kim Leslie O'Neill, Robert Alan Whitehurst, Jaden Duss Evans, Daniel Williar Sharp, Melissa Marie Alegre
-
Publication number: 20110177077Abstract: The present invention relates to novel anti-human PAX 5 antibodies capable of binding to one or more epitopes located within the C-terminal regulatory domain of PAX 5. In particular the invention relates to an antibody, antigen binding fragment or recombinant protein thereof, which is capable of specific binding to an epitope located within the C-terminal fragment of human PAX 5 protein, wherein said epitope comprises from 3 to 17 amino acid residues of amino acid sequence GSPYYYSAAARGAAPPA (SEQ ID NO:2). The invention also relates to immunogenic peptide sequences for the production of the antibodies, diagnostic and therapeutic applications comprising using the antibodies and formulations comprising thereof.Type: ApplicationFiled: June 25, 2009Publication date: July 21, 2011Applicant: DAKO DENMARK A/SInventors: Kirsten Damgaard Hoff, Jakob O. Gjørret, Kurt Pii, Sussie Steen Jensen, Henrik Winther
-
Patent number: 7981421Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: January 13, 2010Date of Patent: July 19, 2011Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
-
Patent number: 7982013Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: GrantFiled: September 28, 2009Date of Patent: July 19, 2011Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
-
Patent number: 7982015Abstract: The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.Type: GrantFiled: May 2, 2005Date of Patent: July 19, 2011Assignee: Genentech, Inc.Inventors: Fred de Sauvage, Audrey Goddard, Austin L. Gurney, Jo-Anne Hongo, Victoria Smith